Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|June 1, 2021
- Ophthalmology Times: June 1, 2021
- Volume 46
- Issue 09
Ventriloquist eye exam
Author(s)Jon Carter
Check out the latest cartoon!
Advertisement
Articles in this issue
over 5 years ago
Quest continues for topical treatments for posterior segmentover 5 years ago
Ophthalmology: A pioneer in the field of artificial intelligenceover 5 years ago
Research: Treatment targets steroid-induced OHTover 5 years ago
IPL offers glaucoma biomarker for early-stage diseaseover 5 years ago
Targeting human retinal progenitor cell injections for RPover 5 years ago
AI predictive ability benefits from free text data in EHRsover 5 years ago
Home IOP monitoring may be aftereffect of COVID-19 pandemicover 5 years ago
Benefits of topography-guided treatments for irregular corneasover 5 years ago
Taking a step forward in glaucoma patient careAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5